Skip to content
value.today

Metacrine, Inc.

🇺🇸 San Diego, California, USAPharmaceuticalsFounded 2014
Total raised
$125 M
3 rounds on record
Latest round
$65 M
Jun 2018
First round on record
Jan 2015
Today
Private
No later event on record

Funding rounds

3 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Metacrine, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jun 2018$65 MNo. 3$50 to $250 million

Metacrine, Inc.: Raise no. 3, Jun 2018

Investors in this round

26 investors had bought by the notice of Jun 20, 2018: 26 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 14 investors are named for Metacrine, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$65 M of $65 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Kenneth Song · Executive Officer, Director
  • Patricia Millican · Executive Officer
  • Amir Nashat · Director
  • Carol Gallagher · Director
  • Kristina Burow · Director
  • Richard Heyman · Director
  • Robert Adelman · Director
  • Ronald Evans · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Kenneth Song, President and CEO. Source: SEC Form D, newest notice filed Jun 20, 2018. Read the notice at the SEC.

equitySEC
Nov 2017$22 MNo. 2$10 to $50 million

Metacrine, Inc.: Raise no. 2, Nov 2017

Investors in this round

7 investors had bought by the notice of Dec 13, 2017: 7 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 14 investors are named for Metacrine, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$22 M of $22 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Ken Song · Executive Officer, Director
  • Patricia Millican · Executive Officer
  • Amir Nashat · Director
  • Carol Gallagher · Director
  • Kristina Burow · Director
  • Richard Heyman · Director
  • Robert Adelman · Director
  • Ronald Evans · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Ken Song, President and CEO. Source: SEC Form D, newest notice filed Dec 13, 2017. Read the notice at the SEC.

equitySEC
Jan 2015$38 MNo. 1$10 to $50 million

Metacrine, Inc.: Raise no. 1, Jan 2015

Investors in this round

20 investors had bought by the notice of Nov 9, 2016: 20 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 14 investors are named for Metacrine, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$38 M of $38 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Ken Song · Executive Officer, Director
  • Trisha Millican · Executive Officer
  • Amir Nashat · Director
  • Kristina Burow · Director
  • Richard Heyman · Director
  • Robert Adelman · Director
  • Ronald Evans · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Total Offering amount includes $338,456.61 of securities issued upon conversion of indebtedness.”

Signed by Ken Song, President and CEO. Source: SEC Form D and 2 amendments, newest notice filed Nov 9, 2016. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Metacrine, Inc. chose not to state its revenue in its newest notice of a funding round (Jun 2018).

    SEC Form D · Jun 2018

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Jun 2018

That is all the official record says: Metacrine, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

14 named in official filings. Open an investor to see everything it has backed.

Investors in Metacrine, Inc.
InvestorKindAmountRoundRoleSource
Alexandria Venture Investments, LLCVenture capitalnot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2020)SEC Form 3
ARCH Venture Fund VIII, L.P.Venture capitalnot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2020)SEC Form 3
ARCH Venture Fund VIII Overage, L.P.Venture capitalnot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2020)SEC Form 3
ARCH Venture Partners VIII, LLCVenture capitalnot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2020)SEC Form 3
ARCH Venture Partners VIII, L.P.Venture capitalnot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2020)SEC Form 3
Nea 16 GP, LLCOthernot statednot statedHeld Series B and C preferred stock, 10% owner (Form 3, 2020)SEC Form 3
NEA Partners 16, L.P.Fund or asset managernot statednot statedHeld Series B and C preferred stock, 10% owner (Form 3, 2020)SEC Form 3
New Enterprise Associates 16, L.P.Fund or asset managernot statednot statedHeld Series B and C preferred stock, 10% owner (Form 3, 2020)SEC Form 3
Polaris Entrepreneurs' Fund VII, L.P.Fund or asset managernot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2020)SEC Form 3
Polaris Management Co. VII, L.L.C.Fund or asset managernot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2020)SEC Form 3
Polaris Partners VII, L.P.Fund or asset managernot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2020)SEC Form 3
venBio Global Strategic Fund, L.P.Fund or asset managernot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2020)SEC Form 3
venBio Global Strategic GP, L.P.Fund or asset managernot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2020)SEC Form 3
venBio Global Strategic GP, Ltd.Companynot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2020)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 3 rounds above had up to 26 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Metacrine, Inc.
NameRoleNamed in
Kenneth SongExecutive officerJun 2018
Patricia MillicanExecutive officerJun 2018
Ken SongExecutive officerDec 2017
Trisha MillicanExecutive officerNov 2016
Neil McDonnellExecutive officerOct 2015
Jackie HernandezExecutive officerApr 2015
Amir NashatDirectorJun 2018
Carol GallagherDirectorJun 2018
Kenneth SongDirectorJun 2018
Kristina BurowDirectorJun 2018
Richard HeymanDirectorJun 2018
Robert AdelmanDirectorJun 2018
Ronald EvansDirectorJun 2018
Ken SongDirectorDec 2017
Neil McDonnellDirectorOct 2015